| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/18/2001 | DE19933173A1 Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ Cyclic peptide derivatives as inhibitors of the integrin alpha¶v¶beta¶6¶ |
| 01/18/2001 | DE19933089A1 Mittel zur Gewerbsregeneration Means for commercial regeneration |
| 01/18/2001 | DE19932157A1 Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln Method for the gentle production of ultrafine microparticles and nanoparticles |
| 01/18/2001 | DE19929488A1 Treatment of inflammation, autoimmune disease and tumors by suppressing activation mediated by the lymphotoxin beta-receptor |
| 01/18/2001 | DE19906921A1 New neuronal cell survival factor, useful for treatment and diagnosis of neuronal diseases, e.g. Alzheimer's disease |
| 01/18/2001 | CA2801979A1 Antigenic meningococcal peptides |
| 01/18/2001 | CA2680437A1 Peptides that lower blood glucose levels |
| 01/18/2001 | CA2379373A1 Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins |
| 01/18/2001 | CA2379345A1 T-cell receptor .gamma. alternate reading frame protein, (tarp) and uses thereof |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2379010A1 Methods of inducing cell death |
| 01/18/2001 | CA2378989A1 Human lim domain proteins |
| 01/18/2001 | CA2378985A1 Atherosclerosis-associated genes |
| 01/18/2001 | CA2378982A1 Methods of inhibiting muscle atrophy |
| 01/18/2001 | CA2378949A1 Growth hormone formulations |
| 01/18/2001 | CA2378740A1 Gene therapy for enhancing and/or inducing angiogenesis |
| 01/18/2001 | CA2378610A1 Human eag2 |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378485A1 Proliferation differentiation factor |
| 01/18/2001 | CA2378465A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | CA2378452A1 Antimicrobial peptides derived from molluscs |
| 01/18/2001 | CA2378451A1 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines |
| 01/18/2001 | CA2378407A1 Dna coding for beta-tubulin and use thereof |
| 01/18/2001 | CA2378402A1 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2378097A1 Induction of a th1-like response in vitro |
| 01/18/2001 | CA2377920A1 Cadmium containing compositions |
| 01/18/2001 | CA2377918A1 Compositions and methods for promoting nerve regeneration |
| 01/18/2001 | CA2377914A1 Analgesic from snake venom |
| 01/18/2001 | CA2377677A1 Hybrid polypeptides with enhanced pharmacokinetic properties |
| 01/18/2001 | CA2377674A1 Novel methods and medicament for treating infectious diseases involving microbial biofilms |
| 01/18/2001 | CA2377228A1 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
| 01/18/2001 | CA2375992A1 Method for controlled production of ultrafine microparticles and nanoparticles |
| 01/18/2001 | CA2375640A1 Dry powder compositions |
| 01/17/2001 | EP1069188A1 Three neprilysin-like membrane metallopeptidases |
| 01/17/2001 | EP1069184A1 Human anion transporter gene implicated in Salla disease and lysosomal sialic acid transport |
| 01/17/2001 | EP1069182A1 Alleviation of symptoms associated with inflammatory disease states, using antibodies to CD18 |
| 01/17/2001 | EP1069137A1 Peptides having thrombospondin-like activity and their therapeutic use |
| 01/17/2001 | EP1069135A1 Proteins having immunomodulatory activity and remedies for immunological diseases |
| 01/17/2001 | EP1069118A1 Process for producing 4-thiazolylmethyl derivative |
| 01/17/2001 | EP1068871A1 Novel methods and medicament for treating infections diseases involving microbial biofilms |
| 01/17/2001 | EP1068799A2 Biological models capable of exhibiting secondary disease manifestations |
| 01/17/2001 | EP1068757A2 A method for controlling connections to a mobile station |
| 01/17/2001 | EP1068357A1 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 01/17/2001 | EP1068347A1 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| 01/17/2001 | EP1068338A2 Enhanced prodrug activation |
| 01/17/2001 | EP1068337A2 Mammalian gene encoding tolloid-like protein |
| 01/17/2001 | EP1068332A2 Recombinant anti-tumor rnase |
| 01/17/2001 | EP1068329A2 FUSION PROTEINS OF $i(MYCOBACTERIUM TUBERCULOSIS) ANTIGENS AND THEIR USES |
| 01/17/2001 | EP1068328A1 Treatment and diagnosis of staphylococcal infections |
| 01/17/2001 | EP1068322A1 U4, a member of the hematopoietin receptor superfamily |
| 01/17/2001 | EP1068321A2 A interleukin-1 receptor antagonist and uses thereof |
| 01/17/2001 | EP1068320A2 Prostapin gene and protein and uses thereof |
| 01/17/2001 | EP1068319A1 PEPTIDE LIGAND HAVING SPECIFIC AFFINITY FOR THE HIV1 RETROVIRUS p24 PROTEIN |
| 01/17/2001 | EP1068318A2 Human nucleic acid sequences from prostate tissue |
| 01/17/2001 | EP1068317A2 Human nucleic acid sequences from prostate tumour tissue |
| 01/17/2001 | EP1068316A1 Blk genes, gene products and uses thereof in apoptosis |
| 01/17/2001 | EP1068315A2 Therapeutic agent for ngf |
| 01/17/2001 | EP1068314A1 Highly active forms of interferon regulatory factor proteins |
| 01/17/2001 | EP1068308A1 Secreted proteins and polynucleotides encoding them |
| 01/17/2001 | EP1068307A1 Secreted proteins and polynucleotides encoding them |
| 01/17/2001 | EP1068300A1 Suppressive monocyte derived cells, process for their preparation and their uses in pharmaceutical compositions |
| 01/17/2001 | EP1068297A1 Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency |
| 01/17/2001 | EP1068296A1 Methods and compositions for eliciting an immune response to a telomerase antigen |
| 01/17/2001 | EP1068257A1 Production of microparticles |
| 01/17/2001 | EP1068242A2 Immune response modulator alpha-2 macroglobulin complex |
| 01/17/2001 | EP1068241A1 Antibody variants and fragments thereof |
| 01/17/2001 | EP1068240A1 Method for sterilising native collagen in liquid medium, resulting native collagen, compositions containing same and uses |
| 01/17/2001 | EP1068239A2 Antioxidant peptides derived from apolipoprotein a-iv |
| 01/17/2001 | EP1068238A1 An integrin heterodimer and a subunit thereof |
| 01/17/2001 | EP1068236A1 Human oxidized ldl receptor |
| 01/17/2001 | EP1068235A1 G-protein coupled receptors |
| 01/17/2001 | EP1068233A1 Transcription factors and their use |
| 01/17/2001 | EP1068232A2 Human antibiotic proteins |
| 01/17/2001 | EP1068231A2 Human nucleic acid sequences of normal ovary tissue |
| 01/17/2001 | EP1068229A1 Peptides |
| 01/17/2001 | EP1068227A1 Retrovirus envelope gylcoprotein mutants and biological applications |
| 01/17/2001 | EP1068223A1 Calcium salts of lipopeptide antibiotics, method for producing same and their use |
| 01/17/2001 | EP1068221A2 Template associated npy y2-receptor agonists |
| 01/17/2001 | EP1068220A1 nrdF |
| 01/17/2001 | EP1068195A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1068155A1 Substrate for array printing |
| 01/17/2001 | EP1067972A1 Multicomponent complex for use with a substrate |
| 01/17/2001 | EP1067959A2 Use of igf1 for treating articular cartilage disorders |
| 01/17/2001 | EP1067958A2 Treatment of cardiac hypertrophy |
| 01/17/2001 | EP1067957A1 Treatment of fibromyalgia with low interferon doses |
| 01/17/2001 | EP1067956A2 Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| 01/17/2001 | EP1067955A2 Pharmaceutical compositions comprising erythropoietin for treatment of cancer |
| 01/17/2001 | EP1067954A1 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE |
| 01/17/2001 | EP1067953A1 Methods for treating an ischemic disorder and improving stroke outcome |
| 01/17/2001 | EP1067952A1 Methods for treatment and prevention of infections |
| 01/17/2001 | EP1067951A2 Use of l-glu-l-trp in the treatment of hiv infection |
| 01/17/2001 | EP1067950A1 Neo-tryptophan |
| 01/17/2001 | EP1067949A1 Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| 01/17/2001 | EP1067946A1 Anti-bacterial protein extracts from seeds of marigold and paprika |
| 01/17/2001 | EP1067944A1 New combined preparation for the treatment of neoplasic diseases or of infectious diseases |
| 01/17/2001 | EP1067940A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 01/17/2001 | EP1067931A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067930A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067929A1 Antagonists of gonadotropin releasing hormone |